GeneDx (WGS) Expected to Announce Earnings on Tuesday

GeneDx (NASDAQ:WGS - Get Free Report) is expected to announce its earnings results before the market opens on Tuesday, February 18th. Analysts expect the company to announce earnings of $0.04 per share and revenue of $82.24 million for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.

GeneDx Trading Down 2.1 %

WGS stock traded down $1.65 during midday trading on Friday, hitting $76.35. 1,267,550 shares of the company's stock were exchanged, compared to its average volume of 1,101,775. GeneDx has a 1-year low of $4.34 and a 1-year high of $98.87. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The business has a 50-day simple moving average of $76.41 and a two-hundred day simple moving average of $60.49. The stock has a market capitalization of $2.10 billion, a PE ratio of -24.55 and a beta of 2.01.

Wall Street Analyst Weigh In

WGS has been the subject of a number of research reports. Craig Hallum lifted their price objective on GeneDx from $70.00 to $95.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. TD Cowen lifted their price objective on GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a research note on Tuesday, January 7th. Wells Fargo & Company lifted their price objective on GeneDx from $34.00 to $75.00 and gave the company an "equal weight" rating in a research note on Wednesday, October 30th. Finally, The Goldman Sachs Group lifted their price objective on GeneDx from $54.00 to $70.00 and gave the company a "neutral" rating in a research note on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $70.67.

Insider Activity at GeneDx

In other GeneDx news, CFO Kevin Feeley sold 35,506 shares of GeneDx stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $93.82, for a total transaction of $3,331,172.92. Following the completion of the sale, the chief financial officer now directly owns 2,472 shares of the company's stock, valued at $231,923.04. The trade was a 93.49 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Katherine Stueland sold 51,420 shares of GeneDx stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $94.48, for a total value of $4,858,161.60. Following the sale, the chief executive officer now directly owns 1,720 shares of the company's stock, valued at $162,505.60. This trade represents a 96.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 320,202 shares of company stock worth $25,011,778. Company insiders own 27.30% of the company's stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.